Management of aminoglycosides in the intensive care unit

Journal of Intensive Care Medicine

Volumn 25, Issue 6, 2010, Pages 327-342

  Radigan, Elizabeth A ^a   Gilchrist, Neil A ^a   Miller, Melissa A ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

aminoglycoside; extended interval; gentamicin; high dose; tobramycin

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIOXIDANT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CARBAPENEM; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; GENTAMICIN; IMIPENEM; MEROPENEM; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALICYLIC ACID; STREPTOMYCIN; TOBRAMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BONE INFECTION; BURN PATIENT; CARDITIS; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENDOCARDITIS; FEBRILE NEUTROPENIA; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HEARING LOSS; HUMAN; INFECTIOUS ARTHRITIS; INJURY; INTENSIVE CARE UNIT; KIDNEY INFECTION; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; OBESITY; OTOTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; PYELONEPHRITIS; RENAL REPLACEMENT THERAPY; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SURGICAL PATIENT; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; MALE;

EID: 78650256741     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066610377968     Document Type: Article

References (142)

1. Obritsch MD, Fish DN, MacLaren R., Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother. 2004 ; 48 (12). 4606-4610.
2. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004 ; 32 (8). 470-485.
3. Munoz-Price LS, Weinstein RA Acinetobacter infection. N Engl J Med. 2008 ; 358 (12). 1271-1281.
4. Crandon JL, Kuti JL, Jones RN, Nicolau DP Comparison of 2002-2006 OPTAMA Programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother. 2009 ; 43 (2). 220-227.
5. Neuhauser MM, Weinstein RA, Rydman R., Danziger LH, Karam G., Quinn JP Antibiotic resistance among gram-negative bacilli in US intensive care units. JAMA. 2003 ; 289 (7). 885-888.
6. DePestel DD, Benninger MS, Danziger L., et al. Cephalosporin use in treatment of patients with penicillin allergies. J Am Pharm Assoc. 2008 ; 48 (4). 530-540.
7. Price KE Aminoglycoside Research 1975-1985: prospects for development of improved agents. Antimicrob Agents Chemother. 1986 ; 29 (4). 543-548.
8. Edson RS, Terrell CL The Aminoglycosides. Mayo Clin Proc. 1999 ; 74 (5). 519-528.
9. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH Once daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 1997 ; 39 (6). 677-686.
10. Blaser J., Stone BB, Groner MC, Zinner SH Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob Agents Chemother. 1987 ; 31 (7). 1054-1060.
11. Moore RD, Lietman PS, Smith CR Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 ; 155 (1). 93-99.
12. Zhanel GG, Hoban DJ, Harding GKM. The postantibiotic effect: a review of in-vitro and in-vivo data. Ann Pharmacother. 1991 ; 25 (2). 153-163.
13. Mingeot-Leclercq MP, Tulkens PM Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999 ; 43 (5). 1003-1012.
14. Olbricht CJ, Fink M., Gutjahr E. Alterations in lysosomal enzymes of the proximal tubule in gentamicin nephrotoxicity. Kidney Int. 1991 ; 39 (4). 639-646.
15. Pannu N., Nadim M. An overview of drug-induced acute kidney injury. Crit Care Med. 2008 ; 36 (4 suppl). S216 - S223.
16. Schentag JJ, Cerra FB, Plaut ME Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients. Antimicrobial Agents and Chemother. 1982 ; 21 (5). 721-726.
17. Smith CR, Lipsky J., Lietman PS Relationship between aminoglycoside induced nephrotoxicity and auditory toxicity. Antimicrobial Agents Chemother. 1979 ; 15 (6). 780-782. (Pubitemid 9202165)
18. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL Prospective evaluation of the effect of an aminoglycoside dosing regimen on rate of observed nephrotoxicity. Antimicrob Agents Chemother. 1999 ; 43 (7). 1549-1555.
19. Oliveira JFP, Silva CA, Barbieri CD, Oliveira GM, Zanetta DMT, Burdmann EA Prevalence and risk factors for aminoglycoside nephrotoxicity in the intensive care units. Antimicrob Agents Chemother. 2009 ; 53 (7). 2887-2891.
20. Bennett WM, Elliott WC, Houghton DC, Gilbert DN, DeFehr J., McCarron DA Reduction of experimental gentamicin nephrotoxicity in rats by dietary calcium loading. Antimicrobial Agents Chemother. 1982 ; 22 (3). 508-512.
21. Abdel-Naim AB, Abdel-Wahab MH, Attia FF Protective effects of vitamin E and probucol against gentamicin-induced nephrotoxicity in rats. Pharmacol Res. 1999 ; 40 (2). 183-187.
22. Bloch R., Luft FC, Rankin LI, Sloan RS, Yum MN, Maxwell DR Protection from gentamicin nephrotoxicity by cephalothin and carbenicilin. Antimicrob Agents Chemother. 1979 ; 15 (1). 46-49.
23. Beauchamp D., Theriault G., Grenier L., et al. Ceftriaxone protects against tobramycin nephrotoxicity. Antimicrob Agents Chemother. 1994 ; 38 (4). 750-756.
24. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995 ; 39 (3). 650-655.
25. de Jager P., van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002 ; 6 (7). 622-627.
26. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004 ; 38 (11). 1538-1544.
27. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Ann NY Acad Sci. 1999 ; 884: 99-109.
28. Casano RA, Johnson DF, Bykhoyskaya Y., Torricelli F., Bigozzi M., Fischel-Ghodsian N. Inherited susceptibility to aminoglycoside ototoxicity: genetic hetereogeneity and clinical implications. Am J Otolaryngol. 1999 ; 20 (3). 151-156.
29. Brummett RE, Fox KE Aminoglycoside induced hearing loss in humans. Antimicrob Agents Chemother. 1989 ; 33 (6). 797-800.
30. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, McDonald WJ High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis. 1992 ; 165 (6). 1026-1032.
31. Govaerts PJ, Claes J., van de Heyring PHV, Jorens PG, Marquet J., De Broe ME Aminoglycoside-induced ototoxicity. Toxicol Lett. 1990 ; 52 (3). 227-251.
32. Moore RD, Smith CR, Lietman PS Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis. 1984 ; 149 (1). 23-30.
33. Gatell JM, Ferran F., Araujo V., et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother. 1987 ; 31 (9). 1383-1387.
34. Sha SH, Qiu JH, Schacht J. Aspirin attenuates gentamicin-induced hearing loss. N Engl J Med. 2006 ; 354 (17). 1856-1857.
35. Feldman L., Efrati S., Eviatar E., et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int. 2007 ; 72 (3). 359-363.
36. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis. 2004 ; 38 (12). 1651-1672.
37. Gilbert TB, Jacobs SC, Quaddoura AA Deafness and prolonged neuromuscular blockade following single-dose peritoneal neomycin irrigation. Can J Anaesth. 1998 ; 45 (6). 568-570.
38. Ferrara BE, Phillips RD Respiratory arrest following administration of intraperitoneal neomycin. Am Surg. 1957 ; 23 (8). 710-712.
39. Warner WA, Sanders E. Neuromuscular blockade associated with gentamicin therapy. JAMA. 1971 ; 215 (7). 1153-1154.
40. Waterman PM, Smith RB Tobramycin-curare interaction. Anesth Analg. 1977 ; 56 (4). 587-588.
41. Wong J., Brown G. Does once-daily dosing of aminoglycosides affect neuromuscular function ? J Clin Pharm Ther. 1996 ; 21 (6). 407-411.
42. Barrons RW Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy. 1997 ; 17 (6). 1220-1232.
43. Begg EJ, Peddie BA, Chambers ST, Boswell DR Comparison of gentamicin dosing regimens using an in-vitro model. J Antimicrob Chemo. 1992 ; 29 (4). 427-433.
44. Nordstrom L., Ringberg H., Cronberg S., Tjernstrom O., Walder M. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity ? J Antimicrob Chemo. 1990 ; 25 (1). 59-73.
45. Mauracher EH, Lau WY, Kartowisastro H., et al. Comparison of once-daily and thrice-daily netilmicin regimens in serious systemic infections: a multi-center study in six Asian countries. Clin Ther. 1989 ; 11 (5). 604-613.
46. Bailey TC, Little JR, Littenberg B., Reichley RM, Dunagan WC A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997 ; 24 (5). 786-795.
47. Beauchamp D., Labrecque G. Aminoglycoside nephrotoxicity: do time and frequency of administration matter? Curr Opin Crit Care. 2001 ; 7 (6). 401-408.
48. Olsen KM, Rudis MI, Rebuck JA, et al. Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med. 2004 ; 32 (8). 1678-1682.
49. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA Experience with once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 2002 ; 28 (7). 936-942.
50. Wallace AW, Jones M., Bertino JS Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy. 2002 ; 22 (9). 1077-1083.
51. Tod MM, Padoin C., Petitjean O. Individualizing aminoglycoside dosing regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Clin Pharmacokinet. 2001 ; 40 (11). 803-814.
52. Streetman DS, Nafziger AN, Destache CJ, Bertino AS Jr. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001 ; 21 (4). 443-451.
53. Boucher BA, Wood GC, Swanson JM Pharmacokinetic changes in critical illness. Crit Care Clin. 2006 ; 22 (2). 255-271.
54. Power BM, Forbes AM, van Heerden PV, Ilett KF Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet. 1998 ; 34 (1). 25-56.
55. Mehrotra R., De Gaudio R., Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med. 2004 ; 30 (12). 2145-2156.
56. Blanchet B., Jullien V., Vinsonneau C., Tod M. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet. 2008 ; 47 (10). 635-654.
57. Hoey LL, Tschida SJ, Rotschafer JC, Guay DRP, Vance-Bryan K. Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. J Burn Care Rehabil. 1997 ; 18 (2). 116-124.
58. Conil JM, Georges B., Breden A., et al. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int J Antimicrob Agents. 2006 ; 28 (3). 226-230.
59. Townsend PL, Fink MP, Stein KL, Murphy SG Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Crit Care Med. 1989 ; 17 (2). 154-157.
60. Pea F., Viale P., Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005 ; 44 (10). 1009-1034.
61. Finnell DL, Davis GA, Cropp CD, Ensom MHH. Validation of the Hartford nomogram in trauma surgery patients. Ann Pharmacother. 1998 ; 32 (4). 417-442.
62. Toschlog EA, Blount KP, Rotondo MF, et al. Clinical predictors of subtherapeutic aminoglycoside levels in trauma patients undergoing once-daily dosing. J Trauma. 2003 ; 55 (2). 255-262.
63. Barletta JF, Johnson SB, Nix DE, Nix LC, Erstad BL Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. J Trauma. 2000 ; 49 (5). 869-872.
64. Pieracci FM, Barie PS, Pomp A. Critical care of the bariatric patient. Crit Care Med. 2006 ; 34 (6). 1796-1804.
65. Sketris I., Lesar T., Zaske DE, Cipolle RJ Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol. 1981 ; 2 (7). 288-293.
66. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983 ; 24 (5). 643-647.
67. Traynor AM, Nafzinger AM, Bertino JS Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother. 1995 ; 39 (2). 545-548.
68. Amin NB, Padhi ID, Touchette MA, Patel RV, Dunfee TP, Anandan JV Characterization of gentamicin pharmacokinetics in patient's hemodialyzed with high-flux polysulfone membranes. Am J Kidney Dis. 1999 ; 34 (2). 222-227.
69. Bohler J., Donauer J., Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl. 1999 ; 72: S24 - S28.
70. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005 ; 41 (8). 1159-1166.
71. Sowinski KM, Magner SJ, Lucksiri A., Scott MK, Hamburger RJ, Mueller BA Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol. 2008 ; 3 (2). 355-361.
72. Johnson CA 2009 dialysis of drugs. Verona, WI: CKD Insights; 2009: 1-56.
73. Kimelblatt BJ, Bradbury K., Chodoff L., Aggour T., Mehl B. Cost-benefit analysis of an aminoglycoside monitoring service. Am J Hosp Pharm. 1986 ; 43 (5). 1205-1209.
74. Destache CJ, Meyer SK, Bittner MJ, Hermann KG Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit. 1990 ; 12 (5). 419-426.
75. Bond CA, Raehl CL Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am J Health-Syst Pharm. 2005 ; 62 (15). 1596-1605.
76. Kane SL, Weber RJ, Dasta JF The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med. 2003 ; 29 (5). 691-698.
77. Kumar A., Roberts D., Wood KE, et al. Duration of hypotension prior to initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006 ; 34 (6). 1589-1596.
78. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008 ; 36 (1). 296-327.
79. Giamarellou H., Zissis NP, Tagari G., Bouzos J. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984 ; 25 (4). 534-536.
80. Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med. 1986 ; 80 (6B). 126-137.
81. Den Hollander JG, Horrevorts AM, van Goor ML, Verbrugh HA, Mouton JW Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1997 ; 41 (1). 95-100.
82. Mouton JW Combination therapy as a tool to prevent emergence of bacterial resistance. Infection. 1999 ; 27 (suppl 2). S24 - S28.
83. Wu YL, Scott EM, Po AL, Tariq VN Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. J Antimicrob Chemother. 1999 ; 44 (3). 389-392.
84. Paul M., Benuri-Silbiger I., Soares-Weiser K., Leibovici L. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomized trials. BMJ. 2004 ; 328 (7441). 668.
85. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 ; 171 (4). 388-416.
86. Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest. 2006 ; 130 (3). 787-793.
87. Baldwin DR, Honeybourne D., Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother. 1992 ; 36 (6). 1176-1180.
88. Bergogne-Berezin E. Predicting the efficacy of antimicrobial agents in respiratory infections: is tissue concentration a valid measure? J Antimicrob Chemother. 1995 ; 35 (3). 363-371.
89. Valcke Y., Pauwels R., Van der Straeten M. Pharmacokinetics of antibiotics in the lungs. Eur Respir J. 1990 ; 3 (6). 715-722.
90. Panidis D., Markantonia SL, Boutzouka E., Karatzas S., Baltopoulos G. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest. 2005 ; 128 (2). 545-552.
91. Kashuba ADM, Nafziger AN, Drusano GL, Bertino JS Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999 ; 43 (3). 623-629.
92. Scaglione F., Esposito S., Leone S., et al. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Respir J. 2009 ; 34 (2). 394-400.
93. Alvarez-Lerma F., Insausti-Ordenana J., Jorda-Marcos R., et al. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med. 2001 ; 27 (3). 493-502.
94. Brun-Buisson C., Sollet JP, Schweich H., Briere S., Petit C. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. Clin Infect Dis. 1998 ; 26 (2). 346-354.
95. Sieger B., Bergman S., Geckler RW, Farkas SA Empiric treatment of hospital-acquired respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med. 1997 ; 25 (10). 1663-1670.
96. Joshi M., Bernstein J., Solomkin J., Wester BA, Kuye O. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group. J Antimicrob Chemother. 1999 ; 43 (3). 389-397.
97. Joshi M., Metzler M., McCarthy M., Olvey S., Kassira W., Cooper A. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6h for treatment of nosocomial pneumonia. Respir Med. 2006 ; 100: 1554-1565.
98. Rubinstein E., Lode H., Grassi C. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group. Clin Infect Dis. 1995 ; 20 (5). 1217-1228.
99. Makhoul IR, Merzbach D., Lichtig C., Berant M. Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pigs: Comparison of aerosol and systemic administration. J Infect Dis. 1993 ; 168 (5). 1296-1299.
100. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999 ; 340 (1). 23-30.
101. Edson R., Brey R., McDonald T., Terrell C., McCarthy J., Thibert J. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc. 2004 ; 79 (9). 1185-1191.
102. Cannella C., Wilkinson ST Acute renal failure associated with inhaled tobramycin. Am J Health Syst Pharm. 2006 ; 63 (19). 1858-1861.
103. Kahler D., Schowengerdt K., Frickler F., Mansfield M., Visner G., Faro A. Toxic serum trough concentrations after administration of nebulized tobramycin. Pharmacotherapy. 2003 ; 23 (4). 543-545.
104. Ahya V., Doyle A., Mendez J., et al. Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J Heart Lung Transplant. 2005 ; 24 (7). 932-935.
105. Izquierdo M., Gomez-Alamillo C., Ortiz F., et al. Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa. Clin Nephrol. 2006 ; 66 (6). 464-467.
106. Rathgeber J., Zielmann S., Panzer C., et al. Prevention of pneumonia by endotracheal micronebulization of tobramycin. Anasthesiol Intensivmed Notfallmed Schmerzther. 1993 ; 28 (1). 23-29.
107. Le Conte P., Potel G., Clementi E., et al. [Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study (Fre). Presse Med. 2000 ; 29: 76-78.
108. Mohr AM, Sifri ZC, Horng HS, et al. Use of aerosolized aminoglycosides in the treatment of Gram-negative ventilator-associated pneumonia. Surg Infect (Larchmt). 2007 ; 8 (3). 349-357.
109. Hallal A., Cohn SM, Namias N., et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect (Larchmt). 2007 ; 8 (1). 73-82.
110. Ehrmann S., Mercier E., Vecellio L., Ternant D., Paintaud G., dequin PF. Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects. Intensive Care Med. 2008 ; 34 (4). 755-762.
111. Platt R., Polk BF, Murdock B., Rosner B. Mortality associated with nosocomial urinary-tract infection. N Engl J Med. 1982 ; 307 (11). 637-642.
112. Laupland KB, Bagshaw SM, Gregson DB, Kirkpatrick AW, Ross T., Church DL Intensive care unit-acquired urinary tract infections in a regional critical care system. Critical Care. 2005 ; 9 (2). R60 - R65.
113. Vidal L., Gafter-Gvili A., Borok S., Fraser A., Leibovici L., Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007 ; 60 (2). 247-257.
114. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2005 ; 111 (23). e394 - e433.
115. Cosgrove SE, Vigliani GA, Campion M., et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009 ; 48 (6). 713-721.
116. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006 ; 355 (7). 653-665.
117. Watanakunakorn C., Baird IM Prognostic factors in Staphylococcus aureus endocarditis and results of therapy with a penicillin and gentamicin. Am J Med Sci. 1977 ; 273 (2). 133-139.
118. Sande MA, Courtney KB Nafcillin-gentamicin synergism in experimental Staphylococcal endocarditis. J Lab Clin Med. 1976 ; 88 (1). 118-124.
119. Korzeniowski O., Sande MA Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med. 1982 ; 97 (4). 496-503.
120. Francioli P., Ruch W., Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis. 1995 ; 21 (6). 1406-1410.
121. Sexton DJ, Tenenbaum MJ, Wilson WR, et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis. 1998 ; 27 (6). 1470-1474.
122. Short WR, Tunkel AR Timing of administration of antimicrobial therapy in bacterial meningitis. Curr Infect Dis Rep. 2001 ; 3 (4). 360-364.
123. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004 ; 39 (9). 1267-1284.
124. Ahmed A., Paris MM, Trujillo M., et al. Once-daily gentamicin therapy for experimental Escherichia coli meningitis. Antimicrob Agents Chemother. 1997 ; 41 (1). 49-53.
125. Andes DR, Craig WA Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am. 1999 ; 13 (3). 595-618.
126. Rodríguez Guardado A., Blanco A., Asensi V., et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother. 2008 ; 61 (4). 908-913.
127. Fulnecky EJ, Wright D., Scheld WM, et al. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. J Infect. 2005 ; 51 (5). e249 - e251.
128. Gilbert VE, Beals Jr JD, Natelson SE, Tyler WA Treatment of cerebrospinal fluid leaks and gram-negative bacillary meningitis with large doses of intrathecal amikacin and systemic antibiotics. Neurosurgery. 1986 ; 18 (4). 402-406.
129. Preston SL, Briceland LL Intrathecal administration of amikacin for treatment of meningitis secondary to cephalosporin-resistant Escherichia coli. Ann Pharmacother. 1993 ; 27 (7-8). 870-873.
130. Hamory B., Ignatiadis P., Sande MA Intrathecal amikacin administration. Use in the treatment of gentamicin-resistant Klebsiella pneumoniae meningitis. JAMA. 1976 ; 236 (17). 1973-1974.
131. Block CS, Cassel R., Koornhof HJ, Robinson RG, Lewer-Allen CM Klebsiella meningitis treated with intrathecal amikacin. Lancet. 1977 ; 1 (8026). 1371-1372.
132. Hughes WT, Armstrong D., Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenia patients with cancer. Clin Infect Dis. 2002 ; 34 (6). 730-751.
133. Paul M., Soares-Weiser K., Leibovici L. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ. 2003 ; 326 (7399). 1111-1120.
134. Gorschluter M., Hahn C., Fixson A. Piperacillin-tazobactam is more effective that ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. Support Care Cancer. 2003 ; 11 (6). 362-370.
135. Sanz MA, Lopez J., Lahuerta JJ, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother. 2002 ; 50 (1). 79-88.
136. Torfoss D., Hoiby A., Tangen JM, et al. Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. J Antimicrob Chemother. 2007 ; 59 (4). 711-717.
137. Rozdzinski E., Kern WV, Reichle A., et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother. 1993 ; 31 (4). 585-598.
138. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Ann Intern Med. 1993 ; 119 (7 Pt 1). 584-593.
139. Gibson J., Johnson L., Snowdon L., et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomized trial. Int J Hematol. 1993 ; 58 (1-2). 63-72.
140. Bailey JA, Virgo KS, DiPiro JT, Nathens AB, Sawyer RG, Mazuski JE Aminoglycosides for intra-abdominal infection: Equal to the challenge? Surg Infect (Larchmt). 2002 ; 3 (4). 315-335.
141. Falagas ME, Matthaiou DK, Karveli EA, Peppas G. Meta-analysis: randomized controlled trials of clindamycin/ami noglycoside vs. beta-lactam monotherapy for the treatment of intra-abdominal infections. Aliment Pharmacol Ther. 2007 ; 25 (5). 537-556.
142. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004 ;351(16): 1645-1654.